Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Zbigniew P. Kortylewicz"'
Autor:
Janina Baranowska-Kortylewicz, Zbigniew P. Kortylewicz, Erin M. McIntyre, John G. Sharp, Don W. Coulter
Publikováno v:
Current Enzyme Inhibition. 19
Background: Emerging data indicate that BCHE, a gene encoding the enzyme butyrylcholinesterase, is a negative prognostic marker in MYCN-amplified neuroblastoma. Levels of butyrylcholinesterase in children newly diagnosed with neuroblastoma are propor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5bbd2687a50d3287fc06ac8c48e30a
https://doi.org/10.2174/1573408019666230206151403
https://doi.org/10.2174/1573408019666230206151403
Publikováno v:
Drug Development Research. 81:62-69
The role of theranostics in cancer management is growing so is the selection of vectors used to deliver these modalities to cancer cells. We describe biological evaluation of a novel theranostic agent targeted to microtubules. Methyl N-[5-(3'-[131 I]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ce089bffbaa4934143bbf16fe46f17
https://doi.org/10.1002/ddr.21604
https://doi.org/10.1002/ddr.21604
Publikováno v:
J Labelled Comp Radiopharm
Neuroblastoma, the most common extracranial solid tumor in children, accounts for nearly 8% of childhood cancers in the United States. It is a disease with pronounced clinical and biological heterogeneities. The amplification of MYCN, whose key tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58479f5a4211f8f16f7b5b14bdbbeab7
https://europepmc.org/articles/PMC7483288/
https://europepmc.org/articles/PMC7483288/
Publikováno v:
Cancer Biother Radiopharm
Background: Resistance of cancer to chemo- and radiotherapy remains a major clinical problem. This study contributes to the ongoing search for agents that can bypass this resistance by developing a novel antimitotic theranostic. Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c937b2ec56fa35b57ffd55b2a62fb7
https://europepmc.org/articles/PMC7044783/
https://europepmc.org/articles/PMC7044783/
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 61:749-756
Microtubules are a target for a broad spectrum of drugs used as chemotherapeutics to treat hematological malignancies and solid tumors. Most of these drugs have significant dose-limiting toxicities including peripheral neuropathies that can be debili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af9d6b84a2a1b257cb44829304ef4f3
https://doi.org/10.1002/jlcr.3631
https://doi.org/10.1002/jlcr.3631
Publikováno v:
Journal of medicinal chemistry. 63(5)
High risk neuroblastoma often recurs, even with aggressive treatments. Clinical evidence suggests that proliferative activities are predictive of poor outcomes. This report describes syntheses, characterization, and biological properties of theranost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7a3e6b9a4284f5ff284c96b3fe383d
https://pubmed.ncbi.nlm.nih.gov/31268317
https://pubmed.ncbi.nlm.nih.gov/31268317
Autor:
Jake A. Luther, Janina Baranowska-Kortylewicz, Don W. Coulter, Stephen P. Enke, Vivek Verma, Angela D. Boettner, Zbigniew P. Kortylewicz
Publikováno v:
Journal of pediatric hematology/oncology. 39(4)
Blood-based biomarkers are important in the detection of the disease and in the assessment of responses to therapy. In this study, butyrylcholinesterase was evaluated as a potential biomarker in newly diagnosed neuroblastoma (NB) patients at diagnosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54ebc77b104b9297c5db743b3777b33
https://pubmed.ncbi.nlm.nih.gov/28375942
https://pubmed.ncbi.nlm.nih.gov/28375942
Autor:
Katherine A. Estes, Charles A. Enke, Elizabeth Mack, Zbigniew P. Kortylewicz, Janina Baranowska-Kortylewicz, R. Lee Mosley
Publikováno v:
The Prostate. 75:8-22
BACKGROUND The androgen receptor (AR) plays a dominant role in the pathogenesis of prostate cancer. 5-Radioiodo-3′-O-(17β-succinyl-5α-androstan-3-one)-2′-deoxyuridin-5′-yl phosphate (RISAD-P) is an AR-targeting reagent developed for noninvasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed65dfcca212c4fec2094ef57f4c3aed
https://doi.org/10.1002/pros.22885
https://doi.org/10.1002/pros.22885
Publikováno v:
The Prostate. 74:1634-1646
BACKGROUND The androgen receptor (AR) axis, the key growth and survival pathway in prostate cancer, remains a prime target for drug development. 5-Radioiodo-3′-O-(17β-succinyl-5α-androstan-3-one)-2′-deoxyuridin-5′-yl phosphate (RISAD-P) is th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6d031fbe398a907b220ff734f4f3c2c
https://doi.org/10.1002/pros.22880
https://doi.org/10.1002/pros.22880
Autor:
Michio Abe, Zbigniew P. Kortylewicz, Janina Baranowska-Kortylewicz, Elizabeth Mack, Charles A. Enke
Publikováno v:
Cancers; Volume 3; Issue 2; Pages: 2501-2515
Cancers, Vol 3, Iss 2, Pp 2501-2515 (2011)
Cancers
Cancers, Vol 3, Iss 2, Pp 2501-2515 (2011)
Cancers
Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c628c7bdaddbefe17f0e10b9e0137d
https://doi.org/10.3390/cancers3022501
https://doi.org/10.3390/cancers3022501